Loading...
XNAS
FATE
Market cap124mUSD
Dec 05, Last price  
1.08USD
1D
-1.82%
1Q
6.93%
Jan 2017
-56.97%
IPO
-84.46%
Name

Fate Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:FATE chart
P/E
—
P/S
9.14
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.76%
Rev. gr., 5y
5.00%
Revenues
14m
-78.55%
1,170,0002,670,000971,00002,431,0004,402,0004,106,0004,740,00010,680,00031,434,00055,846,00096,300,00063,533,00013,631,000
Net income
-186m
L+15.74%
-13,427,000-14,239,000-20,894,000-25,883,000-29,992,000-33,462,000-42,952,000-66,598,000-97,708,000-170,300,000-206,301,000-255,056,000-160,928,000-186,262,000
CFO
-123m
L-7.10%
-12,145,000-13,274,000-15,373,000-22,419,000-18,397,000-29,823,000-36,905,000-38,650,000-83,175,000-39,229,000-162,870,000-248,208,000-132,263,000-122,874,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
URL
https://fatetherapeutics.com/
IPO date
Oct 01, 2013
Employees
551
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT